Switzerland-based biotech company focused on Immuno-Transcriptomic oncology solutions
Novigenix has raised €22M across 2 funding rounds from 1 investor, most recently a Grant round in Apr 2025. Based in Lausanne, Switzerland; active in Healthtech. Data as of 7 Aug 2026.
Timing: in window vs cohort gap · momentum down. Funding-only estimates, not predictions and not investment advice — see signals.
| Date |
|---|
| Stage |
|---|
| Amount |
|---|
| Investors |
|---|
| 2025-04-04 | Grant | €1.8M | European Union (EU) research initiative | View deal → |
| 2022-12-02 | Series B | €20M | — | View deal → |
